You probably heard about BPC-157 and TB-500 the same way most people did. A podcast — Joe Rogan, Huberman Lab, the Diary of a CEO episode with Dr. Alex Tatem. Or because the FDA pulled both compounds off the compounding pharmacy list in 2023. Or because someone at your gym mentioned the “Wolverine stack.”
They get talked about together so often that most people assume they do roughly the same thing. They don’t. Once you understand what each one actually is and what each one is being studied for, the choice between them — or whether to look at both — gets a lot clearer.
This page covers what each compound is, what the published research actually shows, and where the two diverge. Written so it works whether you arrived from a podcast clip or from a cell-biology textbook.
What These Compounds Actually Are
BPC-157 is a synthetic peptide made up of 15 amino acids. It’s the active fragment of a protein originally found in human gastric juice — yes, the stuff in your stomach. Scientists at the University of Zagreb identified the active piece in the 1990s, and that 15-amino-acid synthetic version is what researchers actually use today. The “BPC” stands for Body Protection Compound.
TB-500 is also a synthetic peptide, this time 17 amino acids long. It’s the active fragment of a different protein called thymosin beta-4, which was originally isolated from cow thymus tissue in the 1980s. The 17-residue piece carries the active site of the parent protein, so it gets used as a research stand-in for the larger molecule.
The short version of what each one does in animal-model research:
- BPC-157 has mostly been studied for how it affects new blood vessel formation at sites of tissue damage. The research keyword is “angiogenesis” — building new vasculature.
- TB-500 has mostly been studied for how it changes cell movement, particularly the kind of cell migration that happens during cardiac and corneal tissue repair. The research keyword is “actin dynamics” — how cells reorganize their internal scaffolding to move where they need to go.
If tissue research were construction, BPC-157 looks at building new pipes and wiring (blood vessels supplying nutrients to the work site). TB-500 looks at moving the workers around (cells migrating to where construction is happening). Same construction project, two different sub-questions, different molecular tools to study each one.
Why You’re Reading This
You arrived here for one of a handful of reasons:
- The 2023 FDA reclassification news and what it might mean for the July 2026 PCAC review (both compounds are on the list under reconsideration)
- Your favourite biohacker keeps mentioning the “Wolverine stack” and you want to know what it actually is
- You’re trying to separate legitimate peptide research from peptide marketing
- You want to know what the scientific evidence actually says, in honest terms, about peptides that get a lot of internet attention
Worth being clear about what these are NOT: approved drugs, clinically validated therapies for human use, or compounds with the human safety data that approved medications have. They’re laboratory research tools with substantial preclinical evidence bases and limited human trial data. Anyone selling them as more than that is overreading the science.
The Real Difference
Both compounds get talked about as “tissue-repair peptides” because they show up in animal-model studies of tissue damage. But “tissue-repair” describes the broad research interest area, not the molecular activity.
BPC-157’s main proposed mechanism: vascular biology.
When tissue is damaged, the body has to rebuild the blood-vessel network that supplies the area. BPC-157 has been studied for how it interacts with the molecular signals that drive this vascular rebuilding. The two main pathways researchers have focused on:
- VEGF expression — vascular endothelial growth factor, the main signal that tells the body to grow new blood vessels
- Nitric oxide / eNOS signaling — the system that controls how blood vessels dilate and respond to local conditions
A third pathway involving growth hormone receptors has been proposed in more recent BPC-157 research, but the evidence for it is thinner and the original Zagreb laboratory has openly said it still needs independent replication. That kind of honesty about what the evidence does and doesn’t support is unusual in peptide marketing — and is one of the signals that the BPC-157 research base is genuinely scientific rather than marketing-driven.
TB-500’s main proposed mechanism: cell migration.
Inside every cell is a scaffolding system made of a protein called actin. When cells need to move — for example, when skin cells migrate to cover a wound, or when stem cells move to a damaged area — the actin scaffolding has to reorganize. TB-500 binds to a specific form of actin (the monomer, called “G-actin”) and changes how that scaffolding assembles and disassembles.
The downstream effect studied in animal models is altered cellular migration kinetics. Cells move differently when TB-500 is present in the system. This has been studied in cardiac tissue research (how cells move during cardiac remodeling), corneal research (how epithelial cells migrate during eye-tissue repair), and dermal research.
The summary: BPC-157 affects the infrastructure of tissue (the blood-vessel network). TB-500 affects the movement of cells through that infrastructure. Different parts of the same broad biological process.
Going Deeper into the Mechanism
For readers who want the technical version, the mechanism story has more specifics worth knowing.
BPC-157 acts through three pathways the published research has focused on:
- VEGF expression and angiogenesis. Brcic et al. (2009) documented VEGF upregulation in the L-NAME gastric model — the foundational paper for the angiogenic branch. Subsequent work extended the finding into tendon and corneal contexts.
- Nitric oxide signaling through eNOS. The L-NAME model that Brcic et al. used is itself a pharmacological blockade of nitric oxide synthase, and part of what the 2009 paper demonstrated was that BPC-157 activity is partly rescued by NO signaling.
- Growth hormone receptor sensitization. Chang et al. (2014, Journal of Applied Physiology) extended this into tendon fibroblast research. Sikiric et al. (2018) explicitly note this pathway still awaits meaningful independent replication.
TB-500 acts through G-actin sequestration. By binding monomeric actin and modulating polymerization rate, the peptide shifts cellular migration kinetics. Sosne et al. (2007) characterized the actin-binding domain at residues 17-23 of the parent thymosin beta-4 protein — exactly the LKKTETQ motif that the synthetic fragment reproduces. Bock-Marquette et al. (2004, Nature) is the cardiac reference. Crockford et al. (2010) reviewed the preclinical evidence base across tissue types.
The two pathways genuinely don’t overlap. BPC-157 is doing vascular biology and pathway research. TB-500 is doing cytoskeletal biology and cellular-migration research.
The Evidence Base — What Each One Actually Has Behind It
BPC-157 has roughly thirty years of continuous publication across tendon, gastrointestinal, cardiac, and neurological research contexts. The strongest parts:
- Tendon research — Pevec et al. (2010) examined Achilles tendon research in rat models and reported collagen organization changes at four-week histological endpoints. Chang et al. (2014) extended that to the cellular level. Tendon work is the most independently replicated piece.
- Gastrointestinal protection — Seiwerth et al. (2014) is the standard review. The GI-protection branch is where BPC-157 originated.
- Cardiac and vascular — Tudor et al. (2018) covers the cardiac context.
The weaker parts of BPC-157’s evidence base include the GH-receptor sensitization pathway (limited independent replication outside Zagreb) and dopaminergic/serotonergic modulation in CNS contexts (genuinely thin and handled by serious reviews as an open question).
TB-500 has a different shape of evidence base. Cardiac and corneal work is solid (Bock-Marquette 2004, Sosne 2007). Smart et al. (2011, Nature) characterized thymosin beta-4’s progenitor-cell recruitment activity. Goldstein and Hannappel (2011) reviewed the broader thymosin beta-4 biology across cardiac, neural, and dermal research contexts. Human pharmacokinetic data on TB-500 itself remains limited to early-phase work.
The general shape: BPC-157 has more breadth, TB-500 has more depth in narrower contexts. Neither has the kind of large-scale randomized human trial base that approved therapeutic compounds have. Both sit firmly in preclinical and early-phase research territory.
When Researchers Pair Them — The “Wolverine Stack” Explained
Co-administration of BPC-157 and TB-500 is one of the more common dual-peptide patterns in tissue-repair research, and the reason is structural rather than synergistic.
The two compounds act through non-overlapping mechanisms — angiogenic vs cell-migration — so running them together in a research protocol covers both pathways simultaneously. A tendon-research protocol that includes both compounds can characterize the angiogenic contribution (BPC-157 component) separately from the cellular-migration contribution (TB-500 component).
The “Wolverine” nickname comes from this co-administration pattern. Researchers using both compounds together in tissue-repair protocols started calling the pairing “Wolverine” colloquially, after the Marvel character known for rapid tissue regeneration. The nickname stuck even though it overstates what either compound actually does in any rigorous research context.
Peptigo supplies the BPC-157 / TB-500 research blend as a pre-mixed vial for protocols that need both compounds together.
Where to Start, Depending on Why You’re Here
If you arrived here from any of the following, this is the order to read in:
- Heard about peptides on a podcast (Tatem, Rogan, Huberman) and want to understand tendon-injury research: start with BPC-157. The tendon literature is where the most replicable evidence lives.
- Heard about TB-500 specifically (often in equine veterinary context, where the compound has a longer use history): start with TB-500. The actin-dynamics mechanism is where its evidence is strongest.
- Reading about the FDA Category 2 reclassification and want to understand why specific compounds got picked: read both — both are on the July 2026 PCAC review list, and the regulatory history applies to the class rather than to either compound individually.
- Trying to decide which one to look into for a specific research protocol: the mechanism question above answers this. If your research model is vascular-pathway-focused, BPC-157. If it’s cellular-migration-focused, TB-500. If it’s tissue-repair more broadly and you want to characterize both contributions, the blend.
Side-by-Side
| Property | BPC-157 | TB-500 |
|---|---|---|
| Sequence length | 15 amino acids | 17 amino acids |
| Origin | Fragment of Body Protection Compound from human gastric juice | Active fragment of thymosin beta-4 from calf thymus |
| Mechanism (in one phrase) | Vascular biology / new blood vessel formation | Cell migration / cytoskeletal dynamics |
| Technical mechanism | VEGF / eNOS / GH-receptor pathways | G-actin sequestration |
| Strongest evidence | Tendon, gastrointestinal | Cardiac, corneal, cellular migration |
| Originating laboratory | Sikiric, University of Zagreb (1990s) | Goldstein and colleagues (TB-4); Bock-Marquette and Sosne (fragment) |
| Independent replication | Strong for tendon/GI; weaker for GH-receptor/CNS | Solid for cellular migration phenotype |
| Common research pairing | TB-500 (Wolverine stack) | BPC-157 (Wolverine stack) |
| Reconstitution | Bacteriostatic water; lyophilized | Bacteriostatic water; lyophilized |
| In Peptigo catalog | Yes | Yes |
Common Misconceptions Worth Naming
“BPC-157 and TB-500 do the same thing.” They don’t. The molecular mechanisms are different — vascular vs cytoskeletal. The downstream observation (research interest in tissue repair) overlaps; the actual biology doesn’t.
“TB-500 is just smaller TB-4.” TB-500 is the active fragment of TB-4. The synthetic compound reproduces the LKKTETQ motif and behaves like the active site of the parent protein, but it’s not a generic “smaller version.” The fragment’s research base depends partly on TB-4 papers and partly on its own characterization.
“BPC-157 has stronger human data than TB-500.” Neither has substantial peer-reviewed human pharmacokinetic data at scale. Both sit in preclinical and early-phase research territory. Any vendor or practitioner claiming otherwise is overreading the literature.
“You should always run them together.” Co-administration makes sense when the research question requires both pathways. Single-compound protocols are better for mechanism-isolation work — using only BPC-157 if you want to study the vascular pathway in isolation, only TB-500 if you want the cytoskeletal pathway alone.
Outcome claims about injury recovery. Marketing language that lifts these compounds out of preclinical research framing and into specific human outcome claims is not supported by either compound’s research base. The published literature is about specific molecular mechanisms in animal models. Conflating “studied in tissue-repair research” with concrete human-outcome claims is the gap most peptide marketing exploits.
How Peptigo Sources Both Compounds
Both BPC-157 and TB-500 are supplied by Peptigo as lyophilized powder, with each batch independently tested by Janoshik Analytical at our lab testing partner. The standard testing panel covers HPLC-UV purity, LC-MS identity, LAL bacterial endotoxin quantification, and USP <71> sterility testing. The Certificate of Analysis for each batch is available on the product page.
For protocols that require both compounds, the BPC-157 / TB-500 research blend ships pre-mixed in a single vial. For single-compound protocols, BPC-157 and TB-500 are available individually.
The longer-form mechanism reviews — covering the published literature in more detail than this comparison — live at the BPC-157 mechanism and evidence and TB-500 mechanism and evidence pages.
Related Reading
- BPC-157: Mechanism, Evidence, and What the Literature Actually Says — the deep-dive pillar on BPC-157 specifically
- TB-500: Actin Regulation, Tissue Repair, and the Research Evidence — the deep-dive pillar on TB-500
- Every Peptide Dr. Alex Tatem Mentioned on Diary of a CEO — the podcast-context reference for what’s covered in this comparison
- Browse the BPC-157 and TB-500 product pages for current batch COAs
Related Reading
This article reviews the published research literature for educational purposes. Nothing here is medical advice. All Peptigo products are sold strictly for laboratory and research use only. Not for human or veterinary use.
Last reviewed: April 30, 2026